Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00447421
Status:
TERMINATED
Last Update Posted:
2009-10-28
First Post:
2007-03-12
Brief Title:
A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin Pemetrexed and Radiotherapy
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Phase III Study of Concurrent Cisplatin Pemetrexed and Radiotherapy for Limited Stage Small Cell Lung Cancer
Status:
TERMINATED
Status Verified Date:
2009-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Interim results of another trial showed inferior activity of treatment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the recommended dose of pemetrexed cisplatin and radiotherapy in the treatment of patients with Small Cell Lung Cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H3E-EW-S107 | None | None | None |